Anti-Human CD30 Ligand (TNFSF8) - 25 µg

Quality Tested by Leinco Western Blotting: To detect Human CD30 Ligand this monoclonal antibody can be used at a concentration of 1-2 µg/ml. This monoclonal antibody should be used in conjunction with compatible second-step reagents such as PN:M114 and a chromogenic substrate such as PN:T343. The detection limit for Human CD30 Ligand is 5 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used.

CD30 Ligand

Next Day Ambient

The CD30 ligand is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. Recombinant CD30L has been shown to co-stimulate T cells and to act as a mitogen for Hodgkin's disease derived cell lines. The receptor for CD30L, CD30/ TNFRSF8/CD153, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed- Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis.

CD30 Ligand

AB_2828519

< 0.1 EU/µg as determined by the LAL method

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.